2 years ago

Sensible Biotechnologies Raises $4.2 Million in Pre-Seed Funding to Accelerate mRNA Platform Development

  • Sensible Biotechnologies, an mRNA platform company based in Oxford, UK and Bratislava, Slovakia, has secured $4.2 million in Pre-Seed funding

  • The round was led by BlueYard Capital with participation from Y Combinator, Amino Collective, Civilization Ventures, Recode Health Ventures, and ZAKA, as well as angel investors Florian Schuster, Jason C

  • Foster, and other life science executives

  • The company intends to use the funds to accelerate the development of its cell-based platform for cost-efficient manufacturing of mRNA

  • Sensible Biotechnologies is building a cell-based platform for the production of mRNA, aiming to become an integral part of the biomanufacturing infrastructure and biosecurity framework.

      • ProblemHealthcare

      "developing a cost-efficient manufacturing process for mRNA in the field of therapeutics and vaccines"

      Solution

      "building a cell-based platform for the production of mRNA"

      Covered on